retatrutide phase 2 results obesity nejm 2023 in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 1 Month Retatrutide Results: Clinical

Free fatty acids are released into the bloodstream, but unless you are in a caloric deficit or exercising to oxidize those fatty acids, they are simply re-esterified and stored again

If you have news tips, please send them to [email protected]

Gradual Dose Increase Rapid dose escalation may increase gastrointestinal side effects

Supplies you need before your first retatrutide injection Gathering everything before you start prevents interruptions during reconstitution and injection

Based on data from Phase 2 clinical trials published in the New England Journal of Medicine (2023), retatrutide is administered as a once-weekly subcutaneous injection , typically into the abdomen, thigh, or upper arm

The 5 mg formulation typically represents an intermediate titration dose used to evaluate patient response and minimize gastrointestinal side effects during dose escalation in clinical studies